{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T04:20:57Z","timestamp":1794543657028,"version":"4.9.1"},"publisher-location":"New York, NY","reference-count":159,"publisher":"Springer New York","isbn-type":[{"value":"9781493971039","type":"print"},{"value":"9781493971046","type":"electronic"}],"license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017]]},"DOI":"10.1007\/978-1-4939-7104-6_13","type":"book-chapter","created":{"date-parts":[[2017,6,5]],"date-time":"2017-06-05T01:53:31Z","timestamp":1496627611000},"page":"169-211","source":"Crossref","is-referenced-by-count":2,"title":["Nanoparticle-Based Mycosis Vaccine"],"prefix":"10.1007","author":[{"given":"Swaleha","family":"Zubair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asim","family":"Azhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazoora","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ejaj","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd","family":"Ajmal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Owais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,6]]},"reference":[{"key":"13_CR1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1128\/CMR.19.2.403-434.2006","volume":"19","author":"D Church","year":"2006","unstructured":"Church D, Elsayed S, Reid O et al (2006) Burn wound infections. Clin Microbiol Rev 19:403\u2013434","journal-title":"Clin Microbiol Rev"},{"key":"13_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2011.00018","author":"E Vivier","year":"2011","unstructured":"Vivier E, Ugolini S (2011) Natural killer cells: from basic research to treatments. Front Immunol. doi: 10.3389\/fimmu.2011.00018","journal-title":"Front Immunol"},{"key":"13_CR3","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1097\/QAD.0b013e32833a3967","volume":"24","author":"K Buchacz","year":"2007","unstructured":"Buchacz K, Baker K, Palella J Jr et al (2007) AIDS-defining opportunistic illnesses in US patients, 1994-2007: a cohort study. AIDS 24:1549\u20131559","journal-title":"AIDS"},{"key":"13_CR4","volume-title":"Review of Health care in India","author":"VG Leena","year":"2005","unstructured":"Leena VG, Ravi D, Abhay S (2005) Review of Health care in India. CEHAT, Mumbai. ISBN: 81-89042-40-8"},{"key":"13_CR5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1096\/fj.04-2747rev","volume":"19","author":"M Moghimi","year":"2005","unstructured":"Moghimi M, Hunter C, Murray C (2005) Nanomedicine: current status and future prospects. FASEB J 19:311\u2013330","journal-title":"FASEB J"},{"key":"13_CR6","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s11095-006-0284-8","volume":"23","author":"P Couvreur","year":"2006","unstructured":"Couvreur P, Vauthier C (2006) Nanotechnology: intelligent design to treat complex disease. Pharm Res 23:1417\u20131450","journal-title":"Pharm Res"},{"key":"13_CR7","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/2081295a0","volume":"208","author":"AD Bangham","year":"1965","unstructured":"Bangham AD, Standish MM, Miller N (1965) Cation permeability of phospholipid model membranes: effect of narcotics. Nature 208:1295\u20131297","journal-title":"Nature"},{"key":"13_CR8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1146\/annurev-chembioeng-073009-100847","volume":"1","author":"B Liechty","year":"2010","unstructured":"Liechty B, Kryscio R, Slaughter V, Peppas A (2010) Polymers for drug delivery systems. Annu Rev Chem Biomol Eng 1:149\u2013173","journal-title":"Annu Rev Chem Biomol Eng"},{"key":"13_CR9","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v18.i6.30","volume":"18","author":"M Moghimi","year":"2001","unstructured":"Moghimi M, Hunter C (2001) Capture of stealth nanoparticles by the body\u2019s defences. Crit Rev Ther Drug Carrier Syst 18:527\u2013550","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"13_CR10","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/1061186021000038391","volume":"10","author":"J Panyam","year":"2002","unstructured":"Panyam J, Lof J, O'Leary E, Labhasetwar V (2002) Efficiency of dispatch and infiltrator cardiac infusion catheters in arterial localization of nanoparticles in a porcine coronary model of restenosis. J Drug Target 10:515\u2013523","journal-title":"J Drug Target"},{"key":"13_CR11","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1023\/A:1020398624602","volume":"19","author":"A Quintana","year":"2002","unstructured":"Quintana A, Raczka E, Piehler L et al (2002) Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm Res 19:1310\u20131316","journal-title":"Pharm Res"},{"key":"13_CR12","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1126\/science.1095833","volume":"303","author":"TM Allen","year":"2004","unstructured":"Allen TM, Cullis PR (2004) Drug delivery systems: entering the mainstream. Science 303:1818\u20131822","journal-title":"Science"},{"key":"13_CR13","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/S1359-6446(03)02903-9","volume":"8","author":"SK Sahoo","year":"2003","unstructured":"Sahoo SK, Labhasetwar V (2003) Nanotech approaches to drug delivery and imaging. Drug Discov Today 8:1112\u20131120","journal-title":"Drug Discov Today"},{"key":"13_CR14","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0169-409X(99)00062-9","volume":"41","author":"J Sudimack","year":"2000","unstructured":"Sudimack J, Lee J (2000) Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev 41:147\u2013146","journal-title":"Adv Drug Deliv Rev"},{"key":"13_CR15","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1517\/17425240903071029","volume":"6","author":"C Sinico","year":"2009","unstructured":"Sinico C, Fadda M (2009) Vesicular carriers for dermal drug delivery. Expert Opin Drug Deliv 6:813\u2013825","journal-title":"Expert Opin Drug Deliv"},{"key":"13_CR16","doi-asserted-by":"crossref","first-page":"141","DOI":"10.4103\/0250-474X.25707","volume":"68","author":"S Biju","year":"2006","unstructured":"Biju S, Sushama T, Mishra R et al (2006) Vesicular systems: an overview. Indian J Pharma Sci 68:141\u2013153","journal-title":"Indian J Pharma Sci"},{"key":"13_CR17","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1152\/physrev.00027.2008","volume":"89","author":"B Vollmar","year":"2009","unstructured":"Vollmar B, Menger D (2009) The hepatic microcirculation: mechanistic contributions and therapeutic targets in liver injury and repair. Physiol Rev 89:1269\u20131339","journal-title":"Physiol Rev"},{"key":"13_CR18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4172\/jcsb.1000072","volume":"4","author":"S Singh","year":"2011","unstructured":"Singh S (2011) Membrane permeability in biological systems: a systems biology perspective. J Comput Sci Syst Biol 4:27\u201332","journal-title":"J Comput Sci Syst Biol"},{"key":"13_CR19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1440-1711.2005.01315.x","volume":"83","author":"J Copland","year":"2005","unstructured":"Copland J, Rades T, Davies M et al (2005) Lipid based particulate formulations for the delivery of antigen. Immunol Cell Biol 83:97\u2013105","journal-title":"Immunol Cell Biol"},{"key":"13_CR20","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1124\/jpet.104.078113","volume":"312","author":"C Semple","year":"2005","unstructured":"Semple C, Harasym O, Clow A et al (2005) Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic acid. J Pharmacol Exp Ther 312:1020\u20131026","journal-title":"J Pharmacol Exp Ther"},{"key":"13_CR21","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/S0264-410X(03)00106-3","volume":"21","author":"M Syed","year":"2003","unstructured":"Syed M, Khan A, Nasti H et al (2003) Antigen entrapped in the escheriosomes leads to the generation of CD4(+) helper and CD8(+) cytotoxic T cell response. Vaccine 21:2383\u20132393","journal-title":"Vaccine"},{"key":"13_CR22","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1089\/ten.teb.2007.0435","volume":"14","author":"A Ahmed","year":"2008","unstructured":"Ahmed A, Dare V, Hincke M (2008) Fibrin: a versatile scaffold for tissue engineering applications. Tissue Eng Part B Rev 14:199\u2013215","journal-title":"Tissue Eng Part B Rev"},{"key":"13_CR23","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1111\/j.1538-7836.2005.01365.x","volume":"3","author":"W Mosesson","year":"2005","unstructured":"Mosesson W (2005) Fibrinogen and fibrin structure and functions. J Thromb Haemost 3:1894\u20131904","journal-title":"J Thromb Haemost"},{"key":"13_CR24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1749-6632.2001.tb03491.x","volume":"936","author":"W Mosesson","year":"2001","unstructured":"Mosesson W, Siebenlist R, Meh A (2001) The structure and biological features of fibrinogen and fibrin. Ann N Y Acad Sci 936:11\u201330","journal-title":"Ann N Y Acad Sci"},{"key":"13_CR25","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1055\/s-2001-18870","volume":"27","author":"T Horan","year":"2001","unstructured":"Horan T, Francis W (2001) Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation. Semin Thromb Hemost 27:657\u2013666","journal-title":"Semin Thromb Hemost"},{"key":"13_CR26","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0006-291X(71)80163-8","volume":"44","author":"F Doolittle","year":"1971","unstructured":"Doolittle F, Chen R, Lau F (1971) Hybrid fibrin: proof of the intermolecular nature of- crosslinking units. Biochem Biophys Res Commun 44:94\u2013100","journal-title":"Biochem Biophys Res Commun"},{"key":"13_CR27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1021\/bc9800769","volume":"10","author":"C Schense","year":"1999","unstructured":"Schense C, Hubbell A (1999) Cross-linking exogenous bifunctional peptides into fibrin gels with factor XIIIa. Bioconjug Chem 10:75\u201381","journal-title":"Bioconjug Chem"},{"key":"13_CR28","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1046\/j.1523-1747.1999.00600.x","volume":"112","author":"R Gorodetsky","year":"1999","unstructured":"Gorodetsky R, Clark RA, An J et al (1999) Fibrin microbeads (FMB) as biodegradable carriers for culturing cells and for accelerating wound healing. J Invest Dermatol 112:866\u2013872","journal-title":"J Invest Dermatol"},{"issue":"1","key":"13_CR29","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/jbm.b.30842","volume":"84","author":"G Marx","year":"2008","unstructured":"Marx G, Mou X, Hotovely-Salomon A et al (2008) Heat denaturation of fibrinogen to develop a biomedical matrix. J Biomed Mater Res B Appl Biomater 84(1):49\u201357","journal-title":"J Biomed Mater Res B Appl Biomater"},{"key":"13_CR30","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/sj.ki.5000099","volume":"69","author":"N Shimony","year":"2006","unstructured":"Shimony N, Gorodetsky R, Marx G et al (2006) Fibrin microbeads (FMB) as a 3D platform for kidney gene and cell therapy. Kidney Int 69:625\u2013633","journal-title":"Kidney Int"},{"key":"13_CR31","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1089\/107632702760240571","volume":"8","author":"O Gurevich","year":"2002","unstructured":"Gurevich O, Vexler A, Marx G et al (2002) Fibrin microbeads for isolating and growing bone marrow-derived progenitor cells capable of forming bone tissue. Tissue Eng 8:661\u2013672","journal-title":"Tissue Eng"},{"key":"13_CR32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0142-9612(83)90066-2","volume":"4","author":"H Redl","year":"1983","unstructured":"Redl H, Schlag G, Stanek G, Hirschl A et al (1983) In vitro properties of mixtures of fibrin seal and antibiotics. Biomaterials 4:29\u201332","journal-title":"Biomaterials"},{"key":"13_CR33","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/BF00452091","volume":"114","author":"S Tsourvakas","year":"1995","unstructured":"Tsourvakas S, Hatzigrigoris P, Tsibinos A et al (1995) Pharmacokinetic study of fibrin clot ciprofloxacin complex: an in vitro and in vivo experimental investigation. Arch Orthop Trauma Surg 114:295\u2013297","journal-title":"Arch Orthop Trauma Surg"},{"key":"13_CR34","first-page":"2","volume":"45","author":"I Senderoff","year":"1991","unstructured":"Senderoff I, Sheu T, Sokoloski D (1991) Fibrin based drug delivery systems. J Parenter Sci Technol 45:2\u20136","journal-title":"J Parenter Sci Technol"},{"key":"13_CR35","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1248\/bpb.23.371","volume":"23","author":"H Yoshida","year":"2000","unstructured":"Yoshida H, Yamaoka Y, Shinoyama M et al (2000) Novel drug delivery system using autologous fibrin glue--release properties of anti-cancer drugs. Biol Pharm Bull 23:371\u2013374","journal-title":"Biol Pharm Bull"},{"key":"13_CR36","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1093\/jac\/48.6.861","volume":"48","author":"J Woolverton","year":"2001","unstructured":"Woolverton J, Fulton A, Salstrom J et al (2001) Tetracycline delivery from fibrin controls peritoneal infection without measurable systemic antibiotic. J Antimicrob Chemother 48:861\u2013867","journal-title":"J Antimicrob Chemother"},{"key":"13_CR37","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.biologicals.2003.11.002","volume":"32","author":"R Kumar","year":"2004","unstructured":"Kumar R, Vasantha Bai M, Krishnan K (2004) A freeze-dried fibrin disc as a biodegradable drug release matrix. Biologicals 32:49\u201355","journal-title":"Biologicals"},{"key":"13_CR38","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/BF01740818","volume":"25","author":"M Itokazu","year":"1997","unstructured":"Itokazu M, Yamamoto K, Yang Y et al (1997) The sustained release of antibiotic from freeze-dried fibrin-antibiotic compound and efficacies in a rat model of osteomyelitis. Infection 25:359\u2013363","journal-title":"Infection"},{"key":"13_CR39","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1001\/archopht.120.8.1069","volume":"120","author":"E Simpson","year":"2002","unstructured":"Simpson E, Gilbert A, Rudnick E et al (2002) Transscleral diffusion of carboplatin: an in vitro and in vivo study. Arch Ophthalmol 120:1069\u20131074","journal-title":"Arch Ophthalmol"},{"key":"13_CR40","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1097\/00006982-200410000-00015","volume":"24","author":"T Pardue","year":"2004","unstructured":"Pardue T, Hejny C, Gilbert A et al (2004) Retinal function after subconjunctival injection of carboplatin in fibrin sealant. Retina 24:776\u2013782","journal-title":"Retina"},{"key":"13_CR41","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ejpb.2006.10.016","volume":"65","author":"O H\u00e4feli","year":"2007","unstructured":"H\u00e4feli O, Pauer J, Unnithan J et al (2007) Fibrin glue system for adjuvant brachytherapy of brain tumors with 188Re and 186Re-labeled microspheres. Eur J Pharm Biopharm 65:282\u2013288","journal-title":"Eur J Pharm Biopharm"},{"key":"13_CR42","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1089\/ten.tea.2007.0159","volume":"14","author":"T Hou","year":"2008","unstructured":"Hou T, Xu J, Li Q et al (2008) In vitro evaluation of a fibrin gel antibiotic delivery system containing mesenchymal stem cells and vancomycin alginate beads for treating bone infections and facilitating bone formation. Tissue Eng Part A 14:1173\u20131182","journal-title":"Tissue Eng Part A"},{"key":"13_CR43","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nmat1810","volume":"6","author":"A Janmey","year":"2007","unstructured":"Janmey A, McCormick E, Rammensee S et al (2007) Negative normal stress in semiflexible biopolymer gels. Nat Mater 6:48\u201351","journal-title":"Nat Mater"},{"key":"13_CR44","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0167-7799(90)90139-O","volume":"8","author":"O Smidsr\u00f8d","year":"1990","unstructured":"Smidsr\u00f8d O, Skj\u00e5k-Braek G (1990) Alginate as immobilization matrix for cells. Trends Biotechnol 8:71\u201378","journal-title":"Trends Biotechnol"},{"key":"13_CR45","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0022-5347(17)32671-X","volume":"152","author":"A Atala","year":"1994","unstructured":"Atala A, Kim W, Paige T et al (1994) Endoscopic treatment of vesicoureteral reflux with a chondrocyte-alginate suspension. J Urol 152:641\u2013643","journal-title":"J Urol"},{"key":"13_CR46","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0169-409X(97)00124-5","volume":"31","author":"S Wee","year":"1998","unstructured":"Wee S, Gombotz R (1998) Protein release from alginate matrices. Adv Drug Deliv Rev 31:267\u2013285","journal-title":"Adv Drug Deliv Rev"},{"key":"13_CR47","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nnano.2006.111","volume":"1","author":"A Silva","year":"2006","unstructured":"Silva A (2006) Nanomedicine: seeing the benefits of ceria. Nat Nanotechnol 1:92\u201394","journal-title":"Nat Nanotechnol"},{"key":"13_CR48","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1089\/ten.tea.2010.0004","volume":"16","author":"M Kolambkar","year":"2010","unstructured":"Kolambkar M, Peister A, Ekaputra K et al (2010) Colonization and osteogenic differentiation of different stem cell sources on electrospun nanofiber meshes. Tissue Eng Part A 16:3219\u20133230","journal-title":"Tissue Eng Part A"},{"key":"13_CR49","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1111\/j.1745-7254.2005.00180.x","volume":"26","author":"M Chen","year":"2005","unstructured":"Chen M, Wu F, Wang T et al (2005) Preparation of recombinant human bone morphogenetic protein-2 loaded dextran-based microspheres and their characteristics. Acta Pharmacol Sin 26:1093\u20131103","journal-title":"Acta Pharmacol Sin"},{"key":"13_CR50","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1021\/mp900311x","volume":"7","author":"M Bachelder","year":"2010","unstructured":"Bachelder M, Beaudette T, Broaders E et al (2010) In vitro analysis of acetalated dextran microparticles as a potent delivery platform for vaccine adjuvants. Mol Pharm 7:826\u2013835","journal-title":"Mol Pharm"},{"key":"13_CR51","first-page":"176","volume":"393","author":"J Qi","year":"2010","unstructured":"Qi J, Yao P, He F et al (2010) Nanoparticles with dextran\/chitosan shell and BSA\/chitosan core--doxorubicin loading and delivery. Int J Pharm 393:176\u2013184","journal-title":"Int J Pharm"},{"key":"13_CR52","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/icb\/43.1.3","volume":"43","author":"E M\u00fcller","year":"2003","unstructured":"M\u00fcller E (2003) The origin of metazoan complexity: porifera as integrated animals. Integr Comp Biol 43:3\u201310","journal-title":"Integr Comp Biol"},{"key":"13_CR53","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1074\/jbc.M110709200","volume":"277","author":"A Lullo Di","year":"2002","unstructured":"Di Lullo A, Sweeney M, Korkko J et al (2002) Mapping the ligand-binding sites and disease-associated mutations on the most abundant protein in the human, type I collagen. J Biol Chem 277:4223\u20134231","journal-title":"J Biol Chem"},{"key":"13_CR54","first-page":"118","volume":"3","author":"D Wallace","year":"1988","unstructured":"Wallace D, McPherson J, Ellingsworth L et al (1988) Injectable collagen for tissue augmentation. Collagen, Biotechnology 3:118\u2013144","journal-title":"Collagen, Biotechnology"},{"key":"13_CR55","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/jbm.820230809","volume":"23","author":"D Wallace","year":"1989","unstructured":"Wallace D, Rhee W, Reihanian H et al (1989) Injectable cross-linked collagen with improved flow properties. J Biomed Mater Res 23:931\u2013945","journal-title":"J Biomed Mater Res"},{"key":"13_CR56","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/app.1993.070500604","volume":"50","author":"J Rosenblatt","year":"1993","unstructured":"Rosenblatt J, Devereux B, Wallace D (1993) Dynamic rheological studies of hydrophobic interactions in injectable collagen biomaterials. J Appl Polym Sci 50:953\u2013963","journal-title":"J Appl Polym Sci"},{"key":"13_CR57","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1021\/ma00146a034","volume":"18","author":"A Chow","year":"1985","unstructured":"Chow A, Fuller G, Wallace D et al (1985) Rheo-optical response of rod-like chains subject to transient shear flow:2. Two-color birefringence measurements on collagen protein. Macromolecule 18:793\u2013804","journal-title":"Macromolecule"},{"key":"13_CR58","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1524-4725.1988.tb04038.x","volume":"14","author":"M Kligman","year":"1988","unstructured":"Kligman M (1988) Histologic responses to collagen implants in human volunteers: comparison of Zyderm collagen with Zyplast implant. J Dermatol Surg Oncol 14:35\u201338","journal-title":"J Dermatol Surg Oncol"},{"key":"13_CR59","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1001\/archderm.1987.01660360072015","volume":"123","author":"J Stegman","year":"1987","unstructured":"Stegman J, Chu S, Bensch K et al (1987) A light and electron microscopic evaluation of Zyderm collagen and Zyplast implants in aging human facial skin. A pilot study. Arch Dermatol 123:1644\u20131169","journal-title":"Arch Dermatol"},{"key":"13_CR60","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.addr.2003.08.004","volume":"55","author":"G Wallace","year":"2003","unstructured":"Wallace G, Rosenblatt J (2003) Collagen gel systems for sustained delivery and tissue engineering. Adv Drug Deliv Rev 55:1631\u20131649","journal-title":"Adv Drug Deliv Rev"},{"key":"13_CR61","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1056\/NEJM197603042941005","volume":"294","author":"J Koch-Weser","year":"1976","unstructured":"Koch-Weser J, Sellers M (1976) Drug therapy. Binding of drugs to serum albumin (second of two parts). N Engl J Med 294:526\u2013531","journal-title":"N Engl J Med"},{"key":"13_CR62","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1432-1033.1990.tb19319.x","volume":"193","author":"U Kragh-Hansen","year":"1990","unstructured":"Kragh-Hansen U, Minchiotti L, Brennan O et al (1990) Hormone binding to natural mutants of human serum albumin. Eur J Biochem 193:169\u2013174","journal-title":"Eur J Biochem"},{"key":"13_CR63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cccn.2004.04.005","volume":"347","author":"H Prinsen","year":"2004","unstructured":"Prinsen H, de Sain-van der Velden G (2004) Albumin turnover: experimental approach and its application in health and renal diseases. Clin Chim Acta 347:1\u201314","journal-title":"Clin Chim Acta"},{"key":"13_CR64","first-page":"47","volume":"102","author":"S Nair","year":"2006","unstructured":"Nair S, Laurencin T (2006) Polymers as biomaterials for tissue engineering and controlled drug delivery. Adv Biochem Eng Biotechnol 102:47\u201390","journal-title":"Adv Biochem Eng Biotechnol"},{"key":"13_CR65","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1128\/IAI.59.9.2978-2986.1991","volume":"59","author":"H Eldridge","year":"1991","unstructured":"Eldridge H, Staas K, Meulbroek A et al (1991) Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect Immun 59:2978\u20132986","journal-title":"Infect Immun"},{"key":"13_CR66","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0264-410X(93)90011-L","volume":"11","author":"T O'Hagan","year":"1993","unstructured":"O'Hagan T, McGee P, Holmgren J et al (1993) Biodegradable microparticles for oral immunization. Vaccine 11:149\u2013154","journal-title":"Vaccine"},{"key":"13_CR67","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/0142-9612(93)90066-B","volume":"14","author":"H Pistner","year":"1993","unstructured":"Pistner H, Gutwald R, Ordung R et al (1993) Poly(L-lactide): a long-term degradation study in vivo. I Biological results. Biomaterials 14:671\u2013677","journal-title":"Biomaterials"},{"key":"13_CR68","doi-asserted-by":"publisher","DOI":"10.1002\/0471440264.pst384","volume-title":"Encyclopedia of polymer science and technology","author":"L Marten","year":"2002","unstructured":"Marten L (2002) Encyclopedia of polymer science and technology. John Wiley & Sons, Inc., New York. doi: 10.1002\/0471440264.pst384"},{"key":"13_CR69","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.progpolymsci.2007.04.001","volume":"32","author":"Y Lee","year":"2007","unstructured":"Lee Y, Soon Y (2007) Polymeric protein delivery systems. Prog Polym Sci 32:669\u2013697","journal-title":"Prog Polym Sci"},{"key":"13_CR70","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1023\/A:1020765615379","volume":"19","author":"K Mandal","year":"2002","unstructured":"Mandal K, Bostanian A, Graves A et al (2002) Poly(D,L-lactide-co-glycolide) encapsulated poly(vinyl alcohol) hydrogel as a drug delivery system. Pharm Res 19:1713\u20131719","journal-title":"Pharm Res"},{"key":"13_CR71","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF02931982","volume":"6","author":"Y Yeo","year":"2001","unstructured":"Yeo Y, Namjin B, Kinam P (2001) Microencapsulation methods for delivery of protein drugs. Biotechnol Bioprocess Eng 6:213\u2013230","journal-title":"Biotechnol Bioprocess Eng"},{"key":"13_CR72","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/S0142-9612(00)00101-0","volume":"21","author":"C Middleton","year":"2000","unstructured":"Middleton C, Tipton J (2000) Synthetic biodegradable polymers as orthopedic devices. Biomaterials 21:2335\u20132346","journal-title":"Biomaterials"},{"key":"13_CR73","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3390\/polym3031377","volume":"3","author":"K Makadia","year":"2011","unstructured":"Makadia K, Siegel J (2011) Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers (Basel) 3:1377\u20131397","journal-title":"Polymers (Basel)"},{"key":"13_CR74","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/088532828700200103","volume":"2","author":"E Visscher","year":"1987","unstructured":"Visscher E, Robison A, Argentieri J (1987) Tissue response to biodegradable injectable microcapsules. J Biomater Appl 2:118\u2013131","journal-title":"J Biomater Appl"},{"key":"13_CR75","first-page":"307","volume":"10","author":"L Cleland","year":"1993","unstructured":"Cleland L, Powell F, Shire J (1993) The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit Rev Ther Drug Carrier Syst 10:307\u2013377","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"13_CR76","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1126\/science.aaa6097","volume":"347","author":"W Denning","year":"2015","unstructured":"Denning W, Bromley J (2015) Infectious disease. How to bolster the antifungal pipeline. Science 347:1414\u20131416","journal-title":"Science"},{"key":"13_CR77","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1358\/dot.2004.40.2.799425","volume":"40","author":"R Veerareddy","year":"2004","unstructured":"Veerareddy R, Vobalaboina V (2004) Lipid-based formulations of amphotericin B. Drugs Today (Barc) 40:133\u2013145","journal-title":"Drugs Today (Barc)"},{"key":"13_CR78","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0169-409X(99)00061-7","volume":"41","author":"K Agrawal","year":"2000","unstructured":"Agrawal K, Gupta M (2000) Tuftsin-bearing liposomes in treatment of macrophage-based infections. Adv Drug Deliv Rev 41:135\u2013146","journal-title":"Adv Drug Deliv Rev"},{"key":"13_CR79","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/13693780310001624583","volume":"42","author":"Y Shadkchan","year":"2004","unstructured":"Shadkchan Y, Keisari Y, Segal E (2004) Cytokines in mice treated with amphotericin B-intralipid. Med Mycol 42:123\u2013128","journal-title":"Med Mycol"},{"key":"13_CR80","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/0014-5793(93)81760-W","volume":"326","author":"M Owais","year":"1993","unstructured":"Owais M, Ahmed I, Krishnakumar B et al (1993) Tuftsin-bearing liposomes as drug vehicles in the treatment of experimental aspergillosis. FEBS Lett 326:56\u201358","journal-title":"FEBS Lett"},{"key":"13_CR81","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1007\/s11095-004-7672-8","volume":"21","author":"K Masood","year":"2004","unstructured":"Masood K, Feroz M, Rukhsana J et al (2004) Prophylactic role of liposomised chloroquine against murine cryptococcosis less susceptible to fluconazole. Pharm Res 21:2207\u20132212","journal-title":"Pharm Res"},{"key":"13_CR82","first-page":"13","volume":"2","author":"M Arellano","year":"2008","unstructured":"Arellano M, Lonial S (2008) Clinical uses of GM-CSF, a critical appraisal and update. Biologics 2:13\u201327","journal-title":"Biologics"},{"key":"13_CR83","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.vetimm.2008.04.020","volume":"125","author":"L Blanco","year":"2008","unstructured":"Blanco L, Garcia E (2008) Immune response to fungal infections. Vet Immunol Immunopathol 125:47\u201370","journal-title":"Vet Immunol Immunopathol"},{"key":"13_CR84","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/mmy.38.s1.281.292","volume":"38","author":"L Polonelli","year":"2000","unstructured":"Polonelli L, Casadevall A, Han Y et al (2000) The efficacy of acquired humoral and cellular immunity in the prevention and therapy of experimental fungal infections. Med Mycol 38:281\u2013292","journal-title":"Med Mycol"},{"key":"13_CR85","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nri2939","volume":"11","author":"L Romani","year":"2011","unstructured":"Romani L (2011) Immunity to fungal infections. Nat Rev Immunol 11:275\u2013288","journal-title":"Nat Rev Immunol"},{"key":"13_CR86","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1146\/annurev-immunol-020711-074958","volume":"30","author":"M W\u00fcthrich","year":"2012","unstructured":"W\u00fcthrich M, Deepe S Jr, Klein B (2012) Adaptive immunity to fungi. Annu Rev Immunol 30:115\u2013148","journal-title":"Annu Rev Immunol"},{"key":"13_CR87","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s12281-010-0034-6","volume":"4","author":"L Veerdonk van de","year":"2010","unstructured":"van de Veerdonk L, Netea G (2010) T-cell subsets and antifungal host defenses. Curr Fungal Infect Rep 4:238\u2013243","journal-title":"Curr Fungal Infect Rep"},{"key":"13_CR88","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.fgb.2014.11.006","volume":"78","author":"F Gibson","year":"2015","unstructured":"Gibson F, Johnston A (2015) Immunity to Cryptococcus neoformans and C. gattii during cryptococcosis. Fungal Genet Biol 78:76\u201386","journal-title":"Fungal Genet Biol"},{"key":"13_CR89","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3410\/M3-13","volume":"3","author":"B Spellberg","year":"2011","unstructured":"Spellberg B (2011) Vaccines for invasive fungal infections. F1000 Med Rep 3:13","journal-title":"F1000 Med Rep"},{"key":"13_CR90","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3390\/molecules19011085","volume":"19","author":"E Paramythiotou","year":"2014","unstructured":"Paramythiotou E, Frantzeskaki F, Flevari A et al (2014) Invasive fungal infections in the ICU: how to approach, how to treat. Molecules 19:1085\u20131119","journal-title":"Molecules"},{"key":"13_CR91","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1590\/0074-02760150335","volume":"110","author":"P Medici","year":"2015","unstructured":"Medici P, Del Poeta M (2015) New insights on the development of fungal vaccines: from immunity to recent challenges. Mem Inst Oswaldo Cruz 110:966\u2013973","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"13_CR92","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1093\/clinids\/14.Supplement_1.S43","volume":"14","author":"E Anaissie","year":"1992","unstructured":"Anaissie E (1992) Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin Infect Dis 14:S43\u2013S53","journal-title":"Clin Infect Dis"},{"key":"13_CR93","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/BF01962067","volume":"11","author":"M Pfaller","year":"1992","unstructured":"Pfaller M, Wenzel R (1992) Impact of the changing epidemiology of fungal infections in the 1990s. Eur J Clin Microbiol Infect Dis 11:287\u20131291","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"13_CR94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/28.suppl_A.1","volume":"28","author":"D Richardson","year":"1991","unstructured":"Richardson D (1991) Opportunistic and pathogenic fungi. J Antimicrob Chemother 28:1\u201311","journal-title":"J Antimicrob Chemother"},{"key":"13_CR95","first-page":"249","volume-title":"Emerging targets in antibacterial and antifungal","author":"J Walsh","year":"1992","unstructured":"Walsh J (1992) Emerging targets in antibacterial and antifungal. Chapman & Hall, New York, pp 249\u2013373"},{"key":"13_CR96","doi-asserted-by":"crossref","first-page":"86S","DOI":"10.1016\/0002-9343(91)90349-3","volume":"91","author":"N Banerjee","year":"1991","unstructured":"Banerjee N, Emori G, Culver H et al (1991) Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am J Med 91:86S\u201389S","journal-title":"Am J Med"},{"key":"13_CR97","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1128\/CMR.6.4.428","volume":"6","author":"G Emori","year":"1993","unstructured":"Emori G, Gaynes P (1993) An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev 6:428\u2013442","journal-title":"Clin Microbiol Rev"},{"key":"13_CR98","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/clinids\/20.1.77","volume":"20","author":"A Goff","year":"1995","unstructured":"Goff A, Koletar L, Buesching J et al (1995) Isolation of flucanozole-resistant Candida albicans from HIV negativepatients never treated with azoles. Clin Infect Dis 20:77\u201383","journal-title":"Clin Infect Dis"},{"key":"13_CR99","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1128\/AAC.41.1.196","volume":"41","author":"S Nolte","year":"1997","unstructured":"Nolte S, Parkinson T, Falconer J (1997) Isolation and charecterisation of flucanazole and amphoterecin B resistant Candida albicans from blood of two patients with leukemia. Antimicrob Agents Chemother 41:196\u2013199","journal-title":"Antimicrob Agents Chemother"},{"key":"13_CR100","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0002-9343(95)00010-0","volume":"100","author":"H Nguyen","year":"1996","unstructured":"Nguyen H, Peacock E Jr, Morris J et al (1996) The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 100:617\u2013623","journal-title":"Am J Med"},{"key":"13_CR101","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.it.2012.04.008","volume":"33","author":"G Iannitti","year":"2012","unstructured":"Iannitti G, Carvalho A, Romani L (2012) From memory to antifungal vaccine design. Trends Immunol 33:467\u2013474","journal-title":"Trends Immunol"},{"key":"13_CR102","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1128\/IAI.01037-07","volume":"76","author":"J Behnsen","year":"2008","unstructured":"Behnsen J, Hartmann A, Schmaler J et al (2008) The opportunistic human pathogenic fungus Aspergillus fumigatus evades the host complement system. Infect Immun 76:820\u2013827","journal-title":"Infect Immun"},{"key":"13_CR103","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.coi.2014.01.014","volume":"28","author":"G Nanjappa","year":"2014","unstructured":"Nanjappa G, Klein S (2014) Vaccine immunity against fungal infections. Curr Opin Immunol 28:27\u201333","journal-title":"Curr Opin Immunol"},{"key":"13_CR104","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11046-011-9473-z","volume":"173","author":"M Poeta Del","year":"2012","unstructured":"Del Poeta M, Casadevall A (2012) Ten challenges on Cryptococcus and cryptococcosis. Mycopathologia 173:303\u2013310","journal-title":"Mycopathologia"},{"key":"13_CR105","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1128\/MMBR.00045-10","volume":"75","author":"S Shapiro","year":"2011","unstructured":"Shapiro S, Robbins N, Cowen E (2011) Regulatory circuitry governing fungal development, drug resistance, and disease. Microbiol Mol Biol Rev 75:213\u2013267","journal-title":"Microbiol Mol Biol Rev"},{"key":"13_CR106","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/BF01964059","volume":"8","author":"H Kirkpatrick","year":"1989","unstructured":"Kirkpatrick H (1989) Chronic mucocutaneous candidiasis. Eur J Clin Microbiol Infect Dis 8:448\u2013456","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"13_CR107","first-page":"279","volume-title":"Candidiasis: pathogenesis, diagnosis and treatment","author":"GP Bodey","year":"1993","unstructured":"Bodey GP (1993) Hematogenous and major organ candidiasis. In: Bodey GP (ed) Candidiasis: pathogenesis, diagnosis and treatment. Raven, New York, pp 279\u2013329"},{"key":"13_CR108","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1128\/IAI.58.11.3810-3812.1990","volume":"58","author":"M Casanova","year":"1990","unstructured":"Casanova M, Mart\u00ednez P, Chaffin L (1990) Fab fragments from a monoclonal antibody against a germ tube mannoprotein block the yeast-to-mycelium transition in Candida albicans. Infect Immun 58:3810\u201338112","journal-title":"Infect Immun"},{"key":"13_CR109","first-page":"153","volume":"3","author":"H Buckley","year":"1968","unstructured":"Buckley H, Lucas J, Hattler G Jr et al (1968) Defective cellular immunity associated with chronic mucocutaneous moniliasis and recurrent staphylococcal botryomycosis: immunological reconstitution by allogeneic bone marrow. Clin Exp Immunol 3:153\u2013169","journal-title":"Clin Exp Immunol"},{"key":"13_CR110","first-page":"797","volume":"18","author":"C Hoh","year":"1996","unstructured":"Hoh C, Lin P, Chan L et al (1996) Successful allogeneic bone marrow transplantation in severe chronic mucocutaneous candidiasis syndrome. Bone Marrow Transplant 18:797\u2013800","journal-title":"Bone Marrow Transplant"},{"key":"13_CR111","first-page":"121","volume":"19","author":"E Cutler","year":"1976","unstructured":"Cutler E (1976) Acute systemic candidiasis in normal and congenitally thymic-deficient (nude) mice. J Reticuloendothel Soc 19:121\u2013124","journal-title":"J Reticuloendothel Soc"},{"key":"13_CR112","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1128\/IAI.68.4.2363-2365.2000","volume":"68","author":"J Jones-Carson","year":"2000","unstructured":"Jones-Carson J, Vazquez-Torres A, Warner T et al (2000) Disparate requirement for T cells in resistance to mucosal and acute systemic candidiasis. Infect Immun 68:2363\u20132365","journal-title":"Infect Immun"},{"key":"13_CR113","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/BF00436521","volume":"84","author":"H Tabeta","year":"1984","unstructured":"Tabeta H, Mikami Y, Abe F et al (1984) Studies on defense mechanisms against Candida albicans infection in congenitally athymic nude (nu\/nu) mice. Mycopathologia 84:107\u2013113","journal-title":"Mycopathologia"},{"key":"13_CR114","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/BF02918174","volume":"14","author":"L Romani","year":"1995","unstructured":"Romani L, Cenci E, Menacci A et al (1995) T helper cell dichotomy to Candida albicans: implications for pathology, therapy, and vaccine design. Immunol Res 14:148\u2013162","journal-title":"Immunol Res"},{"key":"13_CR115","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1093\/infdis\/168.6.1449","volume":"168","author":"F Bistoni","year":"1993","unstructured":"Bistoni F, Cenci E, Mencacci A et al (1993) Mucosal and systemic T helper cell function after intragastric colonization of adult mice with Candida albicans. J Infect Dis 168:1449\u20131157","journal-title":"J Infect Dis"},{"key":"13_CR116","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1099\/13500872-145-7-1631","volume":"145","author":"B Ashman","year":"1999","unstructured":"Ashman B, Fulurija A, Papadimitriou M (1999) Both CD4+ and CD8+ lymphocytes reduce the severity of tissue lesions in murine systemic cadidiasis, and CD4+ cells also demonstrate strain-specific immunopathological effects. Microbiology 145:1631\u20131640","journal-title":"Microbiology"},{"key":"13_CR117","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0002-9343(86)90510-3","volume":"81","author":"P Bodey","year":"1986","unstructured":"Bodey P (1986) Infection in cancer patients. A continuing association. Am J Med 81:11\u201326","journal-title":"Am J Med"},{"key":"13_CR118","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0002-9343(97)90050-4","volume":"103","author":"M Nasser","year":"1997","unstructured":"Nasser M, Melgar R, Longworth L et al (1997) Incidence and risk of developing fungal prosthetic valve endocarditis after nosocomial candidemia. Am J Med 103:25\u201332","journal-title":"Am J Med"},{"key":"13_CR119","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0002-9343(89)80392-4","volume":"87","author":"J Bross","year":"1989","unstructured":"Bross J, Talbot GH, Maislin G et al (1989) Risk factors for nosocomial candidemia: a case-control study in adults without leukemia. Am J Med 87:614\u2013620","journal-title":"Am J Med"},{"key":"13_CR120","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1001\/archinte.1989.00390100145030","volume":"149","author":"B Wey","year":"1989","unstructured":"Wey B, Mori M, Pfaller A et al (1989) Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med 149:2349\u20132353","journal-title":"Arch Intern Med"},{"key":"13_CR121","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1086\/514580","volume":"26","author":"L MacDonald","year":"1998","unstructured":"MacDonald L, Baker C, Chenoweth C (1998) Risk factors for candidemia in a children's hospital. Clin Infect Dis 26:642\u2013645","journal-title":"Clin Infect Dis"},{"key":"13_CR122","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1001\/archinte.1989.00390110097022","volume":"149","author":"G Lopez-Berestein","year":"1989","unstructured":"Lopez-Berestein G, Bodey GP, Fainstein V et al (1989) Treatment of systemic fungal infections with liposomal amphotericin B. Arch Intern Med 149:2533\u20132536","journal-title":"Arch Intern Med"},{"key":"13_CR123","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1128\/AAC.41.3.575","volume":"41","author":"M Ruhnke","year":"1997","unstructured":"Ruhnke M, Schmidt-Westhausen A, Trautmann M (1997) In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 41:575\u2013577","journal-title":"Antimicrob Agents Chemother"},{"key":"13_CR124","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1128\/AAC.41.11.2492","volume":"41","author":"H Sanati","year":"1997","unstructured":"Sanati H, Belanger P, Fratti R et al (1997) A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei. Antimicrob Agents Chemother 41:2492\u20132496","journal-title":"Antimicrob Agents Chemother"},{"key":"13_CR125","doi-asserted-by":"crossref","first-page":"5623","DOI":"10.1128\/JCM.41.12.5623-5632.2003","volume":"41","author":"C Hazen","year":"2003","unstructured":"Hazen C, Baron J, Colombo L et al (2003) Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion. J Clin Microbiol 41:5623\u20135632","journal-title":"J Clin Microbiol"},{"key":"13_CR126","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nrmicro1179","volume":"3","author":"B Anderson","year":"2005","unstructured":"Anderson B (2005) Evolution of antifungal-drug resistance: mechanisms and pathogen fitness. Nat Rev Microbiol 3:547\u2013556","journal-title":"Nat Rev Microbiol"},{"key":"13_CR127","doi-asserted-by":"crossref","first-page":"i5","DOI":"10.1093\/jac\/dki218","volume":"56","author":"D Richardson","year":"2005","unstructured":"Richardson D (2005) Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother 56:i5\u2013i11","journal-title":"J Antimicrob Chemother"},{"key":"13_CR128","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0002-9343(94)90300-X","volume":"97","author":"A Sangeorzan","year":"1994","unstructured":"Sangeorzan A, Bradley F, He X et al (1994) Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med 97:339\u2013346","journal-title":"Am J Med"},{"key":"13_CR129","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/jac\/36.5.751","volume":"36","author":"M Johnson","year":"1995","unstructured":"Johnson M, Warnock W (1995) Azole drug resistance in yeasts. J Antimicrob Chemother 36:751\u2013755","journal-title":"J Antimicrob Chemother"},{"key":"13_CR130","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1093\/clinids\/14.Supplement_1.S120","volume":"14","author":"F Meunier","year":"1992","unstructured":"Meunier F, Aoun M, Bitar N (1992) Candidemia in immunocompromised patients. Clin Infect Dis 14:S120\u2013S125","journal-title":"Clin Infect Dis"},{"key":"13_CR131","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/sti.77.3.212","volume":"77","author":"J White","year":"2001","unstructured":"White J, Habib R, Vanthuyne A et al (2001) Combined topical flucytosine and amphotericin B for refractory vaginal Candida glabrata infections. Sex Transm Infect 77:212\u2013213","journal-title":"Sex Transm Infect"},{"key":"13_CR132","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1128\/CMR.17.2.255-267.2004","volume":"17","author":"M Kojic","year":"2004","unstructured":"Kojic M, Darouiche O (2004) Candida infections of medical devices. Clin Microbiol Rev 17:255\u2013267","journal-title":"Clin Microbiol Rev"},{"key":"13_CR133","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/349369a0","volume":"349","author":"G Ada","year":"1991","unstructured":"Ada G (1991) Vaccine development. Real and imagined dangers. Nature 349:369","journal-title":"Nature"},{"key":"13_CR134","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/13693780500035979","volume":"43","author":"B Mochon","year":"2005","unstructured":"Mochon B, Cutler E (2005) Is a vaccine needed against Candida albicans? Med Mycol 43:97\u2013115","journal-title":"Med Mycol"},{"key":"13_CR135","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0195-6701(98)90242-0","volume":"39","author":"C Huang","year":"1998","unstructured":"Huang C, Lin Y, Leu S et al (1998) Yeast carriage on hands of hospital personnel working in intensive care units. J Hosp Infect 39:47\u201355","journal-title":"J Hosp Infect"},{"key":"13_CR136","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000067911","volume":"45","author":"R Hilleman","year":"2002","unstructured":"Hilleman R (2002) Overview of the needs and realities for developing new and improved vaccines in the 21st century. Intervirology 45:199\u2013211","journal-title":"Intervirology"},{"key":"13_CR137","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0264-410X(02)00436-X","volume":"21","author":"J Milstien","year":"2002","unstructured":"Milstien J, Lambert S (2002) Emergency response vaccines--a challenge for the public sector and the vaccine industry. Vaccine 21:146\u2013154","journal-title":"Vaccine"},{"key":"13_CR138","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1046\/j.1365-3083.2001.00944.x","volume":"54","author":"M Owais","year":"2001","unstructured":"Owais M, Massod K, Agrewala N et al (2001) Use of liposome as an immunopotentiating delivery system: in perspective of vaccine development. Scand J Immunol 54:125\u2013132","journal-title":"Scand J Immunol"},{"key":"13_CR139","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1128\/AAC.24.5.787","volume":"24","author":"F Naider","year":"1983","unstructured":"Naider F, Shenbagamurthi P, Steinfeld S et al (1983) Synthesis and biological activity of tripeptidyl polyoxins as antifungal agents. Antimicrob Agents Chemother 24:787\u2013796","journal-title":"Antimicrob Agents Chemother"},{"key":"13_CR140","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0140-6736(03)14472-8","volume":"362","author":"W Denning","year":"2003","unstructured":"Denning W (2003) Echinocandin antifungal drugs. Lancet 362:1142\u20131151","journal-title":"Lancet"},{"key":"13_CR141","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0738-081X(00)00145-0","volume":"18","author":"S Farah","year":"2000","unstructured":"Farah S, Ashman B, Challacombe J (2000) Oral candidosis. Clin Dermatol 18:553\u2013562","journal-title":"Clin Dermatol"},{"key":"13_CR142","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.tim.2004.03.006","volume":"12","author":"L Fidel Jr","year":"2004","unstructured":"Fidel L Jr (2004) History and new insights into host defense against vaginal candidiasis. Trends Microbiol 12:220\u2013227","journal-title":"Trends Microbiol"},{"key":"13_CR143","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/clinids\/24.2.275","volume":"24","author":"M Nucci","year":"1997","unstructured":"Nucci M, Colombo AL, Spector N et al (1997) Breakthrough candidemia in neutropenic patients. Clin Infect Dis 24:275\u2013276","journal-title":"Clin Infect Dis"},{"key":"13_CR144","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1128\/IAI.63.11.4211-4218.1995","volume":"63","author":"A Casadevall","year":"1995","unstructured":"Casadevall A (1995) Antibody immunity and invasive fungal infections. Infect Immun 63:4211\u20134218","journal-title":"Infect Immun"},{"key":"13_CR145","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1034\/j.1399-302X.1999.140306.x","volume":"14","author":"J Hannula","year":"1999","unstructured":"Hannula J, Saarela M, Jousimies-Somer H et al (1999) Age-related acquisition of oral and nasopharyngeal yeast species and stability of colonization in young children. Oral Microbiol Immunol 14:176\u2013182","journal-title":"Oral Microbiol Immunol"},{"key":"13_CR146","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2217\/nnm.13.21","volume":"9","author":"A Chauhan","year":"2014","unstructured":"Chauhan A, Zubair S, Nadeem A et al (2014) Escheriosome-mediated cytosolic delivery of PLK1-specific siRNA: potential in treatment of liver cancer in BALB\/c mice. Nanomedicine (Lond) 9:407\u2013420","journal-title":"Nanomedicine (Lond)"},{"key":"13_CR147","doi-asserted-by":"crossref","unstructured":"Singha H, Mallick I, Jana C et al (2008) Escheriosomes entrapped DNA vaccine co-expressing Cu-Zn superoxide dismutase and IL-18 confers protection against Brucella abortus. Microbes Infect 10:1089\u20131096","DOI":"10.1016\/j.micinf.2008.05.007"},{"key":"13_CR148","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1126\/science.1103773","volume":"307","author":"J Loftus","year":"2005","unstructured":"Loftus J, Fung E, Roncaglia P et al (2005) The genome of the basidiomycetous yeast and human pathogen Cryptococcus neoformans. Science 307:1321\u20131324","journal-title":"Science"},{"key":"13_CR149","doi-asserted-by":"crossref","first-page":"e457","DOI":"10.1371\/journal.pone.0000457","volume":"2","author":"E Dadachova","year":"2007","unstructured":"Dadachova E, Bryan RA, Huang X et al (2007) Ionizing radiation changes the electronic properties of melanin and enhances the growth of melanized fungi. PLoS One 2:e457","journal-title":"PLoS One"},{"key":"13_CR150","unstructured":"Joseph H, Thomas K, Kyung K et al (1998) Book ISBN: 978-1-55581-501-1"},{"key":"13_CR151","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1471-2180-9-51","volume":"9","author":"M Alvarez","year":"2009","unstructured":"Alvarez M, Burn T, Luo Y et al (2009) The outcome of Cryptococcus neoformans intracellular pathogenesis in human monocytes. BMC Microbiol 9:51. doi: 10.1186\/1471-2180-9-51","journal-title":"BMC Microbiol"},{"key":"13_CR152","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1086\/313757","volume":"30","author":"MS Saag","year":"2000","unstructured":"Saag MS, Graybill RJ, Larsen RA et al (2000) Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 30:710\u2013718","journal-title":"Clin Infect Dis"},{"key":"13_CR153","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1128\/CMR.11.1.121","volume":"11","author":"P Mart\u00ednez","year":"1998","unstructured":"Mart\u00ednez P, Gil L, L\u00f3pez-Ribot L et al (1998) Serologic response to cell wall mannoproteins and proteins of Candida albicans. Clin Microbiol Rev 11:121\u2013141","journal-title":"Clin Microbiol Rev"},{"key":"13_CR154","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1086\/374849","volume":"36","author":"A Vibhagool","year":"2003","unstructured":"Vibhagool A, Sungkanuparph S, Mootsikapun P et al (2003) Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study. Clin Infect Dis 36:1329\u20131331","journal-title":"Clin Infect Dis"},{"key":"13_CR155","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1471-2334-6-118","volume":"6","author":"F Schaars","year":"2006","unstructured":"Schaars F, Meintjes A, Morroni C et al (2006) Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg\/day or 400 mg\/day of fluconazole. BMC Infect Dis 6:118","journal-title":"BMC Infect Dis"},{"key":"13_CR156","doi-asserted-by":"crossref","first-page":"573","DOI":"10.4155\/tde.11.30","volume":"2","author":"E Ahmad","year":"2011","unstructured":"Ahmad E, Fatima T, Owais M et al (2011) Beaded plasma clot: a potent sustained-release, drug-delivery system. Ther Deliv 2:573\u2013583","journal-title":"Ther Deliv"},{"key":"13_CR157","doi-asserted-by":"publisher","DOI":"10.1002\/0471140864.psa03fs13","author":"T Wingfield","year":"2001","unstructured":"Wingfield T (2001) Protein precipitation using ammonium sulfate. Curr Protoc Protein Sci. doi: 10.1002\/0471140864.psa03fs13","journal-title":"Curr Protoc Protein Sci"},{"key":"13_CR158","doi-asserted-by":"crossref","first-page":"5667","DOI":"10.1046\/j.0014-2956.2001.02507.x","volume":"268","author":"N Ahmad","year":"2001","unstructured":"Ahmad N, Masood K, Owais M (2001) Fusogenic potential of prokaryotic membrane lipids. Implication in vaccine development. Eur J Biochem 268:5667\u20135675","journal-title":"Eur J Biochem"},{"key":"13_CR159","doi-asserted-by":"crossref","first-page":"6621","DOI":"10.1128\/IAI.70.12.6621-6627.2002","volume":"70","author":"D Pietrella","year":"2002","unstructured":"Pietrella D, Mazzolla R, Lupo P et al (2002) Mannoprotein from Cryptococcus neoformans promotes T-helper type 1 anticandidal responses in mice. Infect Immun 70:6621\u20136627","journal-title":"Infect Immun"}],"container-title":["Methods in Molecular Biology","Vaccines for Invasive Fungal Infections"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4939-7104-6_13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T08:26:40Z","timestamp":1602232000000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4939-7104-6_13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"ISBN":["9781493971039","9781493971046"],"references-count":159,"URL":"https:\/\/doi.org\/10.1007\/978-1-4939-7104-6_13","relation":{"is-part-of":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1007\/978-1-4939-7104-6","asserted-by":"object"}]},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}